Johnson and Johnson
Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Neuroscience Portfolio
Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, Lumateperone, CAPLYTA, Biopharma, M&A
Johnson & Johnson Expands Immunology Portfolio with $1.25B Acquisition of Yellow Jersey Therapeutics
Johnson & Johnson, Yellow Jersey Therapeutics, NM26, atopic dermatitis, bispecific antibody, immunology, Numab Therapeutics
Johnson & Johnson Discontinues Seltorexant Alzheimer’s Program and Trims Neuroscience Pipeline
Johnson & Johnson, seltorexant, Alzheimer’s disease, neuroscience pipeline, clinical trials, pharmaceutical industry
Johnson & Johnson’s Oncology Segment Thrives with Darzalex and Carvykti, Offsetting Stelara Decline
Johnson & Johnson, Darzalex, Carvykti, Stelara, Oncology, Multiple Myeloma, Pharmaceutical Sales
Johnson & Johnson’s Bladder Cancer Treatment Falls Short Against Chemoradiation
Johnson & Johnson, bladder cancer, chemoradiation, TAR-200, SunRISe-1 study
Johnson & Johnson Halts Phase II Dengue Study Amid Shift in R&D Priorities
Johnson & Johnson, Dengue Study, Phase II, Antiviral Drug, Mosnodenvir, Infectious Diseases, R&D Priorities
Johnson & Johnson Invests $2 Billion in New North Carolina Biologics Facility
Johnson & Johnson, North Carolina, Biologics Facility, Pharmaceutical Manufacturing, Investment
Pharmaceutical Giants J&J and Bayer Announce Layoffs of Nearly 300 Employees in New Jersey
Johnson & Johnson, Bayer, layoffs, New Jersey, pharmaceutical industry, job cuts
Johnson & Johnson Boosts Talc Settlement by $1.1 Billion Amid Ongoing Negotiations
Johnson & Johnson, Talc Settlement, $1.1 Billion Increase, Cancer Lawsuits, Bankruptcy Plan
Johnson & Johnson’s 340B Drug Discount Policy Change Rejected by HHS
Johnson & Johnson, 340B drug discount program, Stelara, Xarelto, HHS, HRSA, drug pricing, hospital payments